Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Mak RH, et al. Among authors: hagan mp. J Clin Oncol. 2014 Dec 1;32(34):3801-9. doi: 10.1200/JCO.2014.57.5548. Epub 2014 Nov 3. J Clin Oncol. 2014. PMID: 25366678 Free PMC article.
Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.
Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti A. Lautenschlaeger T, et al. Among authors: hagan mp. Oncologist. 2013 Jun;18(6):685-6. doi: 10.1634/theoncologist.2012-0461. Epub 2013 May 31. Oncologist. 2013. PMID: 23728940 Free PMC article.
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Chakravarti A, et al. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):309-17. doi: 10.1016/j.ijrobp.2004.09.047. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890569
RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. Hagan MP, et al. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):665-72. doi: 10.1016/s0360-3016(03)00718-1. Int J Radiat Oncol Biol Phys. 2003. PMID: 14529770 Clinical Trial.
Superior sulcus lung tumors: impact of local control on survival.
Hagan MP, Choi NC, Mathisen DJ, Wain JC, Wright CD, Grillo HC. Hagan MP, et al. J Thorac Cardiovasc Surg. 1999 Jun;117(6):1086-94. doi: 10.1016/s0022-5223(99)70244-8. J Thorac Cardiovasc Surg. 1999. PMID: 10343256 Free article.
93 results